stockrowNewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- Revenue
- +5,406.9%
- EPS
- +77.1%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
Follow NAMS
Alert me
NewAmsterdam Pharma Company N.V. (NAMS) Net income
NewAmsterdam Pharma Company N.V.'s net income for fiscal 2025 was −$203.8M, compared with −$241.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$204.9M. Over the past ten years it has ranged from −$241.6M (fiscal 2024) to $4.2M (fiscal 2021); the current reading is higher than 25% of that period. NewAmsterdam Pharma Company N.V. ranks 524th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$203.8M | — |
| FY2024 | −$241.6M | — |
| FY2023 | −$176.9M | — |
| FY2022 | −$22.6M | — |
| FY2021 | $4.2M | 9,968.67% |
| FY2020 | $41.5K | 0.00% |
| FY2020 | $41.5K | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$17.4M | — |
| Jun 2026 | −$64.1M | — |
| Mar 2026 | −$48.4M | — |
| Dec 2025 | −$74.9M | — |
| 21 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ADMA ADMA Biologics Inc compare | $182.4M |
| PVLA Palvella Therapeutics, Inc. compare | −$61.7M |
| MBX MBX Biosciences, Inc. compare | −$104.3M |
| XNCR Xencor, Inc. compare | −$163.3M |
| PHVS Pharvaris N.V. compare | −$193.1M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$198.4M |
| NAMS NewAmsterdam Pharma Company N.V. | −$204.9M |
| CLDX Celldex Therapeutics, Inc. compare | −$300.5M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$475.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on NAMS
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement